(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DTB: Vol 31 No 2

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

Safe drug use in patients with cirrhosis

Bol Inf Farmacoter Navar. 2023;31 (2):1-22

Download pdf

Table 14 Safety and dose adjustment for cardiovascular system drugs in patients with cirrhosis.

Cirrhosis is the fibrosis of the liver as a result of different liver damage mechanisms that leads to the inflammation and generation of scar tissue, thus producing nodules. Liver cirrhosis affects both drug pharmacokinetics and pharmacodynamics, and must therefore be taken into consideration when prescribing. The severity and prognosis of cirrhosis are measured using the Child-Pugh classification.
The aim of this bulletin is to help with selection of the most appropriate therapeutic alternative for patients with cirrhosis by providing a series of safety and dose-adjustment guidelines for the drugs most commonly prescribed in primary healthcare.
Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)







Medicines Advice and Information Service
Navarre Health Service

Government of Navarre

Contact us | Accessibility | Legal notice | Site map